John S. Albin

     E-mail: albi0028@umn.edu

     Year Entered: 2005

     Degrees Received:
     University of Kansas
     Microbiology/Spanish
     B.A., 2005

     Honors and Awards:
     -Honors, Years 1 and 2, Medical School
     -Warwick Fellowship, 2008-2009
     -National Institute on Drug Abuse National Research Service Award
     for Individual Predoctoral MD/PhD Fellows, 2009-2013

     Thesis Advisor: Reuben Harris, Ph.D.

     Current Research: My work in the Harris lab focuses on the human DNA cytosine deaminases APOBEC3F and APOBEC3G. Both of these proteins are able to block infection by human immunodeficiency virus type 1 (HIV-1) in the absence of the viral accessory protein virion infectivity factor (Vif). This restrictive activity does not typically manifest in vivo, however, because wild-type Vif-proficient viruses target APOBEC3F and APOBEC3G for degradation.

I am interested in the mechanisms by which APOBEC3F and APOBEC3G may block HIV-1 infection when no longer targeted by Vif. This work anticipates a future in which new classes of antiretroviral drugs will block the interaction of Vif with APOBEC3 proteins. In addition to this developing therapeutic scenario, I am also interested in the implications of APOBEC3 mutational activity for the efficacy of current antiretroviral therapies.

Publications (pubmed):

Albin JS, LaRue RS, Weaver JA, Brown WL, Shindo K, Harjes E, Matsuo H, Harris RS. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J Biol Chem. 2010 Dec 24;285(52):40785-92.

Albin JS, Haché G, Hultquist JF, Brown WL, Harris RS. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J Virol. 2010;84:10209-10219. PMCID: PMC2937771.

Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 2010;38(13):4274-84.

Albin JS, Harris RS. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med. 2010 ;12:e4.

Haché G, Shindo K, Albin JS, Harris RS. Evolution of HIV-1 isolates that use a novel Vif-independent  mechanism to resist restriction by human APOBEC3G. Curr Biol. 2008;18:819-824.

Sundaram P, Han W, Cohen N, Echalier B, Albin J, Timmons L. Caenorhabditis elegans ABCRNAi transporters interact genetically with rde-2 and mut-7. Genetics 2008;178:801-814.